Zydus Lifesciences Limited announced the launch of the world’s first biosimilar of Nivolumab in India, marking a significant step toward expanding access to advanced cancer immunotherapy. The launch positions India at the forefront of biosimilar innovation while addressing long-standing affordability challenges in oncology care.
Tishtha™ aims to expand access to immuno-oncology therapies
The company has introduced the biosimilar under the brand name Tishtha™, which will be used in the treatment of multiple cancer types. According to Zydus, the therapy will be available at nearly one-fourth the cost of the reference drug, substantially easing the financial burden on patients requiring long-term immunotherapy.
Competitive pricing and flexible dosing to reduce treatment costs
To further enhance affordability, Zydus has launched Tishtha™ in two dosage strengths—100 mg priced at ₹28,950 and 40 mg priced at ₹13,950. The dual-strength format will allow oncologists to optimise dosing while minimising drug wastage, a critical factor in improving the overall economics of immunotherapy treatment.
Over five lakh patients could benefit from improved affordability
Zydus estimates that more than five lakh patients in India could benefit from wider access to Nivolumab-based immunotherapy due to the reduced cost. Commenting on the launch, Dr. Sharvil P. Patel, Managing Director, Zydus Lifesciences, said the company remains committed to making advanced cancer care accessible to a broader patient population. “At Zydus, we believe every patient deserves timely access to affordable, advanced cancer care. With the launch of Tishtha™, we are expanding access to Immuno-Oncology through a patient-centric therapy,” he said.
Made-in-India biosimilar ensures supply continuity
Zydus highlighted that access to modern cancer treatment depends on consistency, affordability, and reach. As Tishtha™ has been developed and manufactured in India, the company said it will ensure reliable and uninterrupted availability for patients who require therapy across multiple treatment cycles.
Strengthening Zydus’ biologics and immuno-oncology portfolio
The launch further strengthens Zydus’ position in advanced biologics and immuno-oncology, aligning with its broader strategy to expand access to high-quality biosimilar therapies in India and global markets. As reported by cnbctv18.com, the company is reportedly in discussions to acquire US-based biopharmaceutical firm Ardelyx, according to sources cited by CNBC-TV18. To support the potential acquisition, Zydus is also exploring fundraising through a qualified institutional placement (QIP), the report added.
